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The CDK (cyclin-dependent kinase) family of proteins controls
the eukaryotic cell cycle, and one of these proteins, CDK1, is
required for the onset and maintenance of mitosis. The
activities of CDK family proteins related to cell cycle
control are regulated by associations with cyclin proteins,
interactions with cyclin-dependent kinase inhibitors, such as
p21 and p27, and the phosphorylation-dephosphorylation cycle
of CDK (Morgan, 1997). For instance, the phosphorylation
of CDK1 at threonine-14 and tyrosine-15 by Wee1 and/or
Myt1 kinases negatively controls CDK1 activity, whereas
the dephosphorylation of CDK1 by the CDC25 family
phosphatases activates CDK1, an essential step in the transition
from G2 to M phase. The CDC25 family of dual protein
phosphatases consists of three members, CDC25A, CDC25B,
and CDC25C (Nilsson and Hoffman, 2000). CDC25A is
thought to regulate the G1 to S transition, and CDC25B and C
have been proposed to activate the CDK1/cyclin B1 complex
to advance the cell cycle from G2 to M. Recent reports strongly
suggest that CDC25A also has a function that is essential for
the entry into and maintenance of M phase (Mailand et al.,
2002).
The 14-3-3 family of proteins consists of small, acidic,
highly conserved proteins that are present in all eukaryotic
cells from yeast to mammals. There are seven isotypes present
in mammalian cells. The 14-3-3 proteins are involved in
numerous cellular processes related to signal transduction
(Muslin and Xing, 2000; Tzivion et al., 2001; Yaffe, 2002).
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The dual specificity phosphatase CDC25B positively
controls the G2-M transition by activating CDK1/cyclin B.
The binding of 14-3-3 to CDC25B has been shown to
regulate the subcellular redistribution of CDC25B from the
nucleus to the cytoplasm and may be correlated with
the G2 checkpoint. We used a FLAG-tagged version of
CDC25B to study the differences among the binding sites
for the 14-3-3 subtypes, 14-3-3 b , 14-3-3 e and 14-3-3 s ,
and the relationship between subtype binding and the
subcellular localization of CDC25B. All three subtypes
were found to bind to CDC25B. Site-directed mutagenesis
studies revealed that 14-3-3b bound exclusively near serine-
309 of CDC25B1, which is within a potential consensus
motif for 14-3-3 binding. By contrast, 14-3-3 s bound
preferentially to a site around serine-216, and the presence
of serine-137 and -309 enhanced the binding. In addition to
these binding-site differences, we found that the binding of
14-3-3b drove CDC25B to the cytoplasm and that mutation
of serine-309 to alanine completely abolished the
cytoplasmic localization of CDC25B. However, co-
expression of 14-3-3 s and CDC25B did not affect the
subcellular localization of CDC25B. Furthermore, serine-
309 of CDC25B was sufficient to produce its cytoplasmic
distribution with co-expression of 14-3-3b , even when
other putative 14-3-3 binding sites were mutated. 14-3-3e
resembled 14-3-3b with regard to its binding to CDC25B
and the control of CDC25B subcellular localization. The
results of the present study indicate that two 14-3-3
subtypes can control the subcellular localization of
CDC25B by binding to a specific site and that 14-3-3 s has
effects on CDC25B other than the control of its subcellular
localization.
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These molecules bind to phosphoproteins at specific sequence
motifs, which contain phosphoserine/threonine residues three
amino acids downstream of an arginine (RxxS/T), and thereby
regulate extracellular signaling or stress response pathways
(Muslin et al., 1996; Yaffe et al., 1997). Emerging evidence
suggests that 14-3-3 proteins are key regulators of cell cycle
control, especially at cell cycle checkpoints, where they might
function as negative regulators of DNA damage checkpoints.
For example, one canonical 14-3-3 binding motif, which
contains a phosphorylated serine residue, is similar to the
consensus substrate motif of the checkpoint kinase Chk1
(Sanchez et al., 1997; Hutchins et al., 2000). In fission yeast,
the 14-3-3 proteins Rad24/25 are required for checkpoint
responses and are essential for cell survival (Ford et al., 1994).
One of the 14-3-3 isotype proteins, 14-3-3 s is strongly up-
regulated following genotoxic stress and is a downstream target
of the tumor suppressor p53 (Hermeking et al., 1997).
The involvement of 14-3-3 in the progression from G2 to M
was first suggested by the interactions of isolated 14-3-3b and e
with CDC25B (and CDC25A) and of isolated 14-3-3z with
Wee1 (Conklin et al., 1995; Honda et al., 1997). Accumulated
circumstantial evidence indicates that 14-3-3 negatively controls
the G2-M transition by binding to these regulators. An
association of 14-3-3 with human CDC25C was detected in G1,
S and G2 phases, but not in M phase (Peng et al., 1997). The
binding of 14-3-3 requires the Ser216 of CDC25C, and mutating
this residue to Ala abolishes the interaction. This site is
present in the potential recognition motif for 14-3-3 and is
phosphorylated in vitro by checkpoint kinases, such as Chk1 and
Chk2 (Sanchez et al., 1997; Peng et al., 1998; Matsuoka et al.,
1998; O’Neill et al., 2002). Studies of the interaction between
Xenopus CDC25C and 14-3-3 clearly demonstrated that the
binding of 14-3-3 masks the nuclear localization signal of
CDC25C, thereby causing nuclear exclusion of the protein
without affecting its phosphatase activity (Kumagai et al., 1998;
Kumagai and Dunphy, 1999; Yang et al., 1999). By contrast, the
binding of 14-3-3 to Xenopus Wee1, after Chk1 activation by
DNA damage or by stalled replication, augments Wee1 tyrosine
kinase activity for CDK1 (Wang et al., 2000; Lee et al., 2001;
Rothblum-Oviatt et al., 2001). Thus, the association of 14-3-3
with target proteins could modulate cell cycle progression
through different mechanisms such as subcellular localization
and enzyme activity, depending on cellular signaling.
In the normal cell cycle, CDC25B accumulates only at G2
phase and is degraded when cells exit M phase (Nagata et al.,
1991; Galaktionov and Beach, 1991; Sebastian et al., 1993;
Lammer et al., 1998). Interestingly, the overexpression of
CDC25B induces a mitotic catastrophe by prematurely
activating CDK1/cyclin B1, indicating that CDC25B induces
mitosis more efficiently than CDC25C (Karlsson et al., 1999).
In addition, the exogenous expression of CDC25B can override
the G2 DNA damage checkpoint, and CDC25B is expressed in
certain tumors (Miyata et al., 2001). Therefore, CDC25B has
been proposed to be a potential oncogene acting to abrogate
the DNA damage checkpoint (Galaktionov et al., 1995; Ma
et al., 1999; Yao et al., 1999). Subcellular localization of
CDC25B can be controlled by its association with 14-3-3 at a
specific site on CDC25B2 or B3, Ser323 and might contribute
to stall the cell cycle at the G2 phase following DNA damage
(Mils et al., 2000; Davezac et al., 2000; Forrest and Babrielli,
2001). Ser323 of CDC25B2 or CDC25B3 (the equivalent to
Ser309 of CDC25B1) is a crucial residue in the consensus
14-3-3 binding motif, where it is phosphorylated by the stress
kinase p38 (Bulavin et al., 2001).
In the present study, we have analyzed the binding site
specificity of three 14-3-3 subtypes, 14-3-3 b , e , and s . Our
results indicate that the binding site of 14-3-3 s differs
markedly from those of 14-3-3 b and 14-3-3 e . Moreover, the
interaction of 14-3-3b or 14-3-3e , but not of 14-3-3 s with
CDC25B drives CDC25B from the nucleus into the cytoplasm.
The biological significance of our results is discussed.
Materials and Methods
Cell culture and transfection
HEK293 cells (ATCC number CRL-1573) and U2OS cells (ATCC
number HTB-96) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Sigma, USA) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen, USA), 100 units/ml penicillin and 10 m g/ml
streptomycin. Transient transfections were performed with FuGENE6
(Roche Diagnostics, Germany). For immunoprecipitation, cells were
typically seeded at 1.3 · 106 per well. After 24 hours, cells were
co-transfected with 2.5 m g of FLAG-tagged CDC25B and 1.0 m g of
myc-tagged 14-3-3 DNA. For the indirect immunofluorescence
experiments, cells were plated at a lower density, 2.0 · 105 per well
and transfected after 24 hours with 3.0 m g of CDC25B DNA and
1.5 m g 14-3-3 of DNA. Transfected cells were processed for
immunoblotting, immunoprecipitation, or immunostaining 24 hours
after transfection. Leptomycin B, an inhibitor of CRM1 (exportin1),
was obtained from Minoru Yoshida (RIKEN, Wako, Japan) and was
administered to cells at a dose of 20 ng/ml to induce the nuclear
accumulation of CDC25B.
Plasmids and site-directed mutagenesis
The cDNA of human CDC25B (CDC25B1 subtype), a kind gift from
H. Okayama (University of Tokyo, Japan), was subcloned into the
pEF6B vector (Invitrogen, USA) and expressed in transfected cells
with a C-terminal FLAG tag. For point mutations at putative 14-3-3
binding sites, the following oligonucleotides (and their complements)
were used to change serine to alanine (SA) in human CDC25B cDNA
(CDC25B1). Clones with multiple mutations were generated by
exchanging restriction fragments. The mutations were confirmed by
sequencing.
S81A: 5 ¢ -CTGTCTCGACGGGCAGCCGAATCCTCCCTG-3 ¢ ,
S137A: 5¢ -ATCAGACGCTTCCAGGCTATGCCGGTGAGG-3¢ ,
S216A: 5¢ -GCCCAGAGACCCAGCGCGGCCCCCGACCTG-3¢ ,
S309A: 5¢ -CTCTTCCGCTCTCCGGCCATGCCCTGCAGC-3 ¢ , 
S361A: 5¢ -GTCCTCCGCTCAAAAGCACTGTGTCACGAT-3 ¢ .
The cDNAs of human 14-3-3 b , e , and s were obtained by PCR
amplification with the following oligonucleotides:
14-3-3b forward: 5¢ -ACTTGGAGTCAGCATATGACAATGGAT-3¢ ,
14-3-3b reverse: 5¢ -CACTGGACGGATCCCAAAGCACGAGAA-
3¢ ,
14-3-3e forward: 5¢ -GCCGCTGCCCATATGGATGATCGAGAG-3¢ ,
14-3-3e reverse: 5¢ -CTCTTGTGGGCGGATCCCTCACTGATT-3¢ ,
14-3-3s forward: 5¢ -GTCCCCAGACATATGGAGAGAGCCAGT-
3¢ ,
14-3-3s reverse: 5¢ -GGTGGCGGGCAAGCTTCAGCTCTGGGG-
CTC-3¢ .
PCR products were subcloned into the pEF6 vector. Each 14-3-3
cDNA was expressed in transfected cells in an N-terminal myc-tagged
form.
Antibodies
Anti-FLAG M2 agarose was obtained from Sigma (USA). The rabbit
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anti-FLAG antibody was described previously (Wang et al., 2001).
Rabbit polyclonal and mouse monoclonal anti-myc-tag antibodies
were purchased from Cell Signaling (USA). Antibodies to 14-3-3 b
(C-20), 14-3-3 e (T-16), and 14-3-3 s (N-14) were purchased from
Santa Cruz Biotechnology (USA).
Preparation of crude cell extracts, immunoprecipitation and
immunoblotting
Transfected cells were lysed in immunoprecipitation (IP) buffer (50
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 5 mM EGTA, 1
mM EDTA) supplemented with a protease inhibitor mix and a
phosphatase inhibitor mix. The protease inhibitor mix contained a
1:100 dilution of FOCUS protease arrest (Calbiochem, USA), 5 m g/ml
E64 (Roche Diagnostics, Germany), 0.4 m M cathepsin inhibitor III
(Sigma, USA), 10 m M MG132 (Calbiochem, USA), 20 m M N-acetyl-
leu-leu-norleu-ala (Sigma, USA) and 1 mg/ml Pefabloc®SC (Roche
Diagnostics, Germany). The phosphatase inhibitor mix consisted of a
1:100 dilution of Phosphatase inhibitor cocktail II (Sigma, USA),
20 mM p-nitrophenyl phosphate, 20 mM NaF, 20 mM b -
glycerophosphate, 0.2 m M microcystin-LR (Calbiochem, USA), 0.2
m M calyculin A (Wako, Japan), 0.2 m M okadaic acid (Wako, Japan),
0.1 m M phenylarsin (Sigma, USA), and 0.2 m M cantharidin (Sigma,
USA). FLAG-tagged CDC25B and mutant proteins were
immunoprecipitated using FLAG M2-agarose; myc-tagged 14-3-3
proteins were immunoprecipitated with mouse monoclonal anti-
myc tag antibody followed by protein G-Sepharose (Amersham
Bioscience, USA). Cell lysates and immunoprecipitates were
analyzed on western blots using rabbit polyclonal anti-FLAG (for
CDC25B) or anti-myc antibodies (for exogenous 14-3-3), or 14-3-3
subtype-specific antibodies (for endogenous 14-3-3).
Indirect immunofluorescence microscopy
Transfected HEK293 cells grown on glass coverslips were fixed in
3.7% formaldehyde in PBS and then permeabilized with 0.5% Triton
X-100 in PBS. FLAG-tagged CDC25B and mutants were detected
with rabbit polyclonal anti-FLAG antibody and Alexa-594-
conjugated goat anti-rabbit IgG (Molecular Probes, USA).
Alternatively, myc-tagged 14-3-3 proteins were detected with mouse
monoclonal anti-myc-tag antibody and Alexa-488-conjugated goat
anti-mouse IgG (Molecular Probes, USA). In all samples, DNA was
visualized with 4 ¢ ,6-diamidino-2-phenylindole (DAPI) (Sigma,
USA) at 0.1 m g/ml. To quantify the subcellular localization of
CDC25B, more than 200 transfectant cells were counted and
classified as having nuclear, diffuse or cytoplasmic localization.
Results
Binding of 14-3-3b , e , and s to CDC25B
Several groups have reported the interaction of 14-3-3 isotypes,
such as 14-3-3 b , e , h , and z , with CDC25B (Mils et al., 2000;
Forrest and Gabrielli, 2001). We have isolated 14-3-3 b and e
as proteins that interact with CDC25B in yeast two-hybrid
screening (S.U., A.K., M.O., M.S., M.H., H.N., T.M., Y.I. and
K.Y., unpublished data), obtaining the same results as those
previously reported (Conklin et al., 1995). Apart from these
two 14-3-3 proteins ( b and e) , 14-3-3 s was also reported to be
possibly involved in a DNA damage checkpoint (Hermeking et
al., 1997; Chan et al., 1999, 2000), which prompted us to
isolate its cDNA and analyze its interaction with CDC25B.
We expressed FLAG-tagged CDC25B with myc-tagged
14-3-3b , e or s in HEK293 or U2OS cells and examined their
interaction (Fig. 1). Expression of these proteins was confirmed
in cell extracts prepared from transfected cells, as shown in Fig.
1 (Lysate). CDC25B was immunoprecipitated with anti-FLAG
beads followed by western blotting and detection with either
anti-FLAG or anti-myc antibody to detect CDC25B bound to
14-3-3. The results in Fig. 1 (IP: CDC25B) clearly indicate
that all three 14-3-3 proteins can bind to CDC25B in co-
transfected cells. To further confirm these results, reciprocal
immunoprecipitation and western blot experiments were
conducted in which CDC25B was detected in anti-myc
immunoprecipitates of 14-3-3b , e , or s (Fig. 1, IP: 14-3-3).
Thus, 14-3-3 s was most probably a new CDC25B-interacting
protein.
Binding site specificity of 14-3-3 subtypes
The binding of 14-3-3 proteins to target proteins requires the
specific motif RSxS/T(P)xP, where S/T(P) and x represent
phosphoserine or phosphothreonine, and any amino acid,
respectively (Muslin et al., 1996; Yaffe et al., 1997). The
arginine (R) at position –3 from the phosphorylatable serine
(or threonine) is a minimal requirement. In Xenopus for
instance, after phosphorylation of CDC25 or Wee1 by Chk1 or
other kinases, 14-3-3 e binds to the phosphorylated Ser287 in
the RSPSMP sequence of CDC25 (Kumagai et al., 1998; Yang
et al., 1999) and to the phosphorylated Ser549 in the RSVSFT
sequence of Wee1 (Wang et al., 2000; Lee et al., 2001). There
are several RxxS sites in CDC25B (or in our case, CDC25B1),
Fig. 1. 14-3-3b , 14-3-3 e , and 14-3-3 s bind to CDC25B in
transfected cells. HEK293 (left panels) or U2OS (right panels) cells
were transfected with FLAG-tagged CDC25B together with either
empty vector or one of the myc-tagged 14-3-3 subtypes as described
in Materials and Methods. (Top row) Lysate. Expression of CDC25B
and 14-3-3- subtypes was confirmed in cell lysates with anti-FLAG
antibody against CDC25B or anti-myc antibody against 14-3-3,
respectively. (Middle row) IP: CDC25B (a -FLAG Ab). CDC25B
was immunoprecipitated with anti-FLAG beads followed by western
blotting and detection with anti-FLAG antibody to detect CDC25B
and anti-myc antibody to detect CDC25B-bound 14-3-3. (Bottom
row) IP: 14-3-3 (a -myc Ab. Reciprocal immunoprecipitation;
CDC25B was detected in anti-myc immunoprecipitates. Protein 14-
3-3 subtypes were immunoprecipitated with anti-myc antibody; the
collected 14-3-3 or 14-3-3-bound CDC25B was detected by
immunoblotting. v, empty vector; b , 14-3-3 b , e ; 14-3-3 e , s ; 14-3-3 s .
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of which we chose the following five: 78-RRAS-81, 134-
RFQS-137, 213-RPSS-216, 306-RSPS-309, and 358-RSKS-
361, as shown in Fig. 2A. Of the relevant serine residues,
Ser309 and Ser361 were phosphorylated by p38 in vitro and
Ser309 was reported to be crucial for 14-3-3 binding after
phosphorylation (Bulavin et al., 2001).
To analyze binding site specificity, we constructed three
different groups of mutants in respect to the five above
mentioned phosphorylatable serine sites of CDC25B1.
Members of the first group have only a single mutation
that changed one phosphorylatable serine to a non-
phosphorylatable alanine; these mutants were namend
CDC25B-S81A, S137A, etc. Members of the second group
only remain a single phosphorylatable serine residue and
contain mutations that changed the four serine residues to
alanines; these mutants were named CDC25B-81S, 137S, etc.
The only member of the last group is CDC25B-5SA in which
all five serine residues were mutated to alanines. Using these
mutants and the wild-type CDC25B, we determined the
binding site specificity of 14-3-3 b , e , and s .
Wild-type or mutant CDC25B were co-transfected with
14-3-3b , e , or s . Crude cell extracts were prepared, and
expression of CDC25B and 14-3-3 was confirmed. Protein
extracts were immunoprecipitated with anti-FLAG or anti-myc
antibody, transferred for western blotting and detected with
anti-myc or anti-FLAG antibody, respectively, to assess
binding. We observed similar expression levels of CDC25B
and 14-3-3 in transfected cells (Fig. 2B, Lysate), although
lower levels of CDC25B mutants that failed to interact with
14-3-3, such as 81S and 5SA mutants, were occasionally
detected (S.U., A.K., M.O., M.S., M.H., H.N., T.M., Y.I. and
K.Y., unpublished data).
Interestingly, each 14-3-3 protein bound to a specific site on
CDC25B (Fig. 2B, IP: CDC25B). These results clearly indicate
that the CDC25B point mutation that changed Ser309 to
Ala309, completely abolished 14-3-3 b binding and that
mutations of the other putative binding sites had essentially no
effect on binding when compared with wild-type CDC25B.
Also, experiments with the CDC25B mutant containing a
single phosphorylatable serine revealed that Ser309 was the
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Fig. 2. Binding of 14-3-3 subtypes to CDC25B is site specific.
(A) Putative 14-3-3 consensus binding sites in CDC25B.
(B-D) Mutants of CDC25B were transfected into HEK293 or
U2OS cells either alone or together with 14-3-3 subtypes as
indicated. Recovered CDC25B proteins are indicated (upper
panel of each set of figures). The letters at the top and numbers at
the bottom of each blot represent the CDC25B mutants: wild-
type (1); S81A (2); S137A (3); S216A (4); S309A (5); S361A
(6); 81S (7); 137S (8); 216S (9); 309S (10); 361S (11); 5SA (12).
The definitions of the abbreviations for each mutant are described
in the text. (B) Mutants of CDC25B were co-transfected into
HEK293 cells with 14-3-3 subtypes b , e or s . Protein expression
was determined by immunoblot. Wild-type or mutant CDC25B
proteins were immunoprecipitated with anti-FLAG beads, and
CDC25B-bound 14-3-3 was determined in the lysate (Lysate)
and the immunoprecipitate [IP: CDC25B ( a -FLAG Ab)].
Separate panel ‘long exposure’ shows 14-3-3 subtype s after an
exposure for 1 hour. (C) Mutants of CDC25B were transfected
into HEK293 cells. Recovered CDC25B proteins and CDC25B-
bound endogenous 14-3-3 b (endo-14-3-3b ) or endogenous
14-3-3e (endo-14-3-3e ) were detected with specific
antibodies in the lysate (Lysate) and the immunoprecipitate
[IP: CDC25B ( a -FLAG Ab]. (D) Mutants of CDC25B were
transfected into U2OS cells. Recovered CDC25B and
CDC25B-bound endogenous 14-3-3s (endo-14-3-3s ) were
detected with specific antibodies in the lysate (Lysate) and
the immunoprecipitate [IP: CDC25B (a -FLAG Ab].(E)
Binding of endogenous and transfected 14-3-3 subtypes to
CDC25B mutants. ++, well bound; +, detectably bound; ±,
faintly bound (could be detected only after long exposure); –,
no binding.
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sole site responsible for 14-3-3 b binding. A faint signal was
detected with the CDC25B mutants containing Ser137 or
Ser216, but only after a long exposure time (S.U., A.K., M.O.,
M.S., M.H., H.N., T.M., Y.I. and K.Y., unpublished data).
Exactly the same results were obtained for 14-3-3e binding
(Fig. 2B), i.e. the intact Ser309 fulfills the binding requirement.
Surprisingly, entirely different results were obtained when
14-3-3s was co-expressed with CDC25B. As shown in Fig.
2B, the mutation of Ser309 to Ala309 had little effect on 14-3-
3s binding. Instead, a single mutation changing Ser216
to Ala216 apparently abrogated the binding of 14-3-3 s .
Experiments with single-serine constructs of CDC25B
provided complementary results, indicating that only Ser216 is
responsible for 14-3-3 s binding. Notice, that the amount of
14-3-3s that bound to the CDC25B-S216 mutant was roughly
half the amount of 14-3-3 b or e that bound to the CDC25B-
S309 mutant. Therefore, the affinity of 14-3-3 s for Ser216
seems to be lower than those of 14-3-3 b and e for Ser309.
Furthermore, 14-3-3s bound to two other binding sites, Ser137
and Ser309, although with a lower affinity than the binding to
Ser216 (Fig. 2B, Long exposure).
Binding of endogenous 14-3-3 to CDC25B
Next, we addressed the question of whether endogenous 14-3-3
binds to transfected CDC25B. After transfection of wild-type or
mutant CDC25B, CDC25B was recovered and CDC25-bound
14-3-3b , e , or s was detected with subtype-specific antibodies.
CDC25B was transfected to HEK293 cells to investigate binding
of 14-3-3b and e . U2OS cells were used to determine 14-3-3s
binding because no expression of 14-3-3s was detected in
HEK293 cells. Binding of endogenous 14-3-3b and e is shown
in Fig. 2C and that of 14-3-3s in Fig. 2D. As illustrated, the
results were essentially the same as those for the exogenously
expressed ones. 14-3-3b and e preferentially bound to Ser309
and a mutation to Ala at this site impaired 14-3-3 binding. Unlike
14-3-3b and e , a Ser to Ala mutation at Ser216 eliminated
14-3-3s binding (summarized in Fig. 2E). As clearly indicated,
both endogenous and exogenous 14-3-3b and e preferentially
bind to Ser309, whereas 14-3-3s prefers Ser216. Besides these
two sites, Ser137 seems to be a favored binding site for the three
14-3-3 subtypes tested here because the binding signals are
reduced by mutation at Ser137 (Fig. 2C and D). In respect to the
other putative binding sites, we found no evidence that the
14-3-3 subtypes bind to either Ser81 or Ser361.
Multiple binding sites for 14-3-3s on CDC25B
The results shown in Fig. 2 suggest that 14-3-3 s binds to
CDC25B at multiple sites and possibly requires two sites to
stably bind the protein. To explore this further, we constructed
a series of mutants in which two serine residues were changed
to alanine, and examined the binding of the 14-3-3 subtypes
(Fig. 3). Compared with the single SA mutant (i.e. S216A),
binding of 14-3-3 s to double SA mutants, such as S216/309A,
was weaker or absent. Further work with the double mutants
indicated that either of two sites, Ser137 or Ser309, seem to
work cooperatively with Ser216. These results strongly suggest
that 14-3-3 s requires two sites, Ser216 and Ser137 or Ser216
and Ser309, to interact effectively with CDC25B, and that
14-3-3s might function as a dimer.
14-3-3 binding sites and subcellular localization of
CDC25B
Binding of 14-3-3 to CDC25B was previously reported to
induce the redistribution of CDC25B from the nucleus to the
cytoplasm; the amino acid residue essential for this effect was
shown to be Ser323 of CDC25B3 (or CDC25B2), which
corresponds to Ser309 of CDC25B1 in our experiments
(Davezac et al., 2000; Forrest and Gabrielli, 2001). Therefore,
we analyzed the subcellular localization of CDC25B mutants
expressed in combination with 14-3-3 subtypes that possess
different binding site preferences. To assess the effects of co-
transfection on the subcellular localization of CDC25B, we
distinguished three different distributions [nuclear (N), diffuse
(N=C) and cytoplasmic (C)] of CDC25B (Fig. 4A). The
localization of exogenously expressed CDC25B was mainly
nuclear (Fig. 4B), transfected 14-3-3 b or s was detected in the
cytoplasm (S.U., A.K., M.O., M.S., M.H., H.N., T.M., Y.I. and
K.Y., unpublished data). Upon co-transfection with 14-3-3 b ,
CDC25B exhibited a diffuse distribution (Fig. 4B).
Quantitatively, the percentage of cells with nuclear CDC25B
was reduced from 55% to 30% and that of cells with a diffuse
distribution increased from 38% to 60% when co-expressed
with 14-3-3 b . Based on our results, it is possible that nuclear
localization is disturbed by 14-3-3 binding. Interestingly, the
expression of 14-3-3 s had no effect on the localization of
CDC25B. These results led us to hypothesize that when
14-3-3b binds to Ser309 of CDC25B, it can drive CDC25B
from the nucleus to the cytoplasm, but that 14-3-3 s , which
does not bind primarily to Ser309, has no ability to do so.
Effects of mutations at 14-3-3 binding sites on the
localization of CDC25B
The primary 14-3-3b binding site on CDC25B was Ser309, and
a point mutation at this site that changed serine to alanine
abolished the interaction. If the binding of 14-3-3b is correlated
Fig. 3. Efficient binding of 14-3-3 s to CDC25B requires two
independent sites. HEK293 cells were co-transfected with 14-3-3 s
and a series of CDC25B mutants. Protein expression (Lysate) and
protein binding (IP: CDC25B ( a -FLAG Ab)) were detected. The
letters in the upper panel of Lysate indicate CDC25B wild type and
respective mutants. The definitions of the abbreviations for each
mutant are described in the text.
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with the cytoplasmic localization of CDC25B, 14-3-3b could not
drive the CDC25B mutant out of the nucleus. The results shown
in Fig. 4C indicate that the mutation Ser309 to Ala309 in
CDC25B completely disrupted its cytoplasmic localization with
more than 90% of the mutant protein being located in the nuclei.
In contrast to the wild type, this CDC25B mutant was not
diffused into the cytoplasm by co-expression of 14-3-3b or
14-3-3s . However, mutant S216A behaved like the wild type,
i.e. its subcellular localization was effectively changed from
nuclear to diffuse when co-expressed with 14-3-3b (Fig. 4D).
Moreover, introduction of 14-3-3s did not cause any change in
the distribution of CDC25B. Collectively, these results show that
Ser309 is essential for the cytoplasmic distribution of CDC25B
and that Ser216 does not have any influence on the subcellular
localization of CDC25B, even when 14-3-3s binds to it.
To confirm that the subcellular distribution of CDC25B by
14-3-3b depends on Ser309, we made mutants in which serine
was changed to alanine at four of the five sites that have a single
phosphorylatable serine residue. The mutants were denoted
as CDC25B-81S, CDC25B-137S, CDC25B-216S, CDC25B-
309S and CDC25B-361S (as mentioned in Fig. 2). These
CDC25B mutants were transfected with or without 14-3-3 and
their localizations analyzed. Only CDC25B-309S behaved like
the wild type (Fig. 5B); the other mutants exhibited nuclear
localizations, probably because they possessed the S309A
mutation and could not bind to 14-3-3 b (Fig. 5A). Wild-type
CDC25B and the CDC25B-309S mutant exhibited nuclear
localization in about 60% of the cells (Fig. 5B). As was the
case with wild-type CDC25B (see Fig. 4B), the expression of
14-3-3b antagonized the nuclear localization of CDC25B-309S
and led to a diffuse distribution (Fig. 5B). In contrast to 14-3-
3b , 14-3-3 s did not bind to the mutant and had no effect
on the nuclear localization of CDC25B-309S or wild-type
CDC25B (Fig. 5B). These results strongly suggest that only
Ser309 of CDC25B is required for the control of the
subcellular localization of CDC25B by 14-3-3 b .
Effects of 14-3-3e on the nuclear localization of CDC25B
The results shown in Fig. 2 indicate that Ser309 of CDC25B
is the specific binding site for 14-3-3 e . We examined the effects
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Fig. 4. 14-3-3b but not 14-3-3 s efficiently redistributes CDC25B
from the nucleus to the cytoplasm. HEK293 cells were transfected
with FLAG-tagged CDC25B in combination with empty vector,
myc-tagged 14-3-3 b or myc-tagged 14-3-3 s , followed by
immunostaining with anti-FLAG antibodies to detect the subcellular
localization of CDC25B and with anti-myc antibodies to detect co-
transfected 14-3-3 proteins. Analyses showed that more than 95% of
the cells that expressed CDC25B also expressed the co-transfected
14-3-3 proteins. (A) Exemplary images, showing how the subcellular
distribution of CDC25B was evaluated: N>C, predominantly nuclear;
N=C diffuse; N<C, predominantly cytoplasmic. (B) Wild-type
CDC25B was co-transfected with empty vector (WT), myc-tagged
14-3-3b ( WT+14-3-3b ) or myc-tagged 14-3-3 s ( WT+14-3-3s ) to
quantify the subcellular distribution of CDC25B. Over 200 cells
expressing CDC25B were counted to determine the percentage of
cells that express CDC25B with nuclear, diffuse and cytoplasmic
distribution. Error bars in graphs represent the means+s.d. of three
independent experiments. (C) Transfection with wild-type CDC25B
alone (WT), S309A mutant of CDC25B alone (S309A) and mutant
S309A in combination with myc-tagged 14-3-3 b ( S309A+14-3-3 b )
or myc-tagged 14-3-3 s ( S309A+14-3-3 s ). Over 200 cells expressing
CDC25B were counted to determine the percentage of cells that
express CDC25B with nuclear, diffuse and cytoplasmic distribution.
Error bars in graphs represent the means+s.d. of three independent
experiments. (D) Transfection with wild-type CDC25B alone (WT),
S216A mutant of CDC25B alone (S216A) and mutant S216A in
combination with myc-tagged 14-3-3 b ( S216A+14-3-3 b ) or myc-
tagged 14-3-3 s ( S216A+14-3-3 s ). Over 200 cells expressing
CDC25B were counted to determine the percentage of cells that
express CDC25B with nuclear, diffuse and cytoplasmic distribution.
Error bars in graphs represent the means+s.d. of three independent
experiments.
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of 14-3-3e on the subcellular localization of CDC25B in three
sets of experiments. First, 14-3-3 e was co-transfected with
wild-type CDC25B and CDC25B-distribution (as defined
above and in Fig. 4A) was analyzed by counting the cells. Co-
expression of 14-3-3 e reduced the percentage of cells with
nuclear localization of CDC25B from 55% to 47% and
concomitantly increased the percentage of cells displaying a
diffuse pattern from 40% to 55% (Fig. 6A). Second, 14-3-3 e
was co-transfected with the CDC25B-309S mutant. Here, the
nuclear localization of CDC25B decreased from 60% to 37%,
whereas its diffuse distribution increased from 35% to 55%
(Fig. 6B). We found no effects of the co-expression of 14-3-3 e
on the subcellular localization of the CDC25B-S309A mutant
(Fig. 6C). In summary, the results with 14-3-3 e were exactly
the same as those obtained with 14-3-3 b and different from
those with 14-3-3 s .
Effects of 14-3-3b binding on the nuclear import of
CDC25B
Several previous studies demonstrated that treating cells with
leptomycin B (LMB), a CRM1 (exportin1) inhibitor, disrupts
the cytoplasmic localization of CDC25B (Nishi et al., 1994;
Kudo et al., 1998; Karlsson et al., 1999; Davezac et al., 2000)
(Fig. 7A). Therefore, it might be that 14-3-3 b -binding slows
down the nuclear import of CDC25B by LMB. After
transfecting CDC25B with or without 14-3-3 b , cells were
treated with LMB and the nuclear accumulation of CDC25B
was measured. As shown in Fig. 7B, co-expression of
exogenous 14-3-3 b efficiently inhibited the nuclear import of
CDC25B. Notice that this effect was not observed when
14-3-3s was co-transfected with CDC25B. These results
suggest that 14-3-3 b masks the nuclear localizing signal
(NLS) of CDC25B, which is located about 30 amino acids
downstream of Ser309.
Discussion
It has long been believed that higher eukaryotic cells have two
dual specificity phosphatases, CDC25B and CDC25C, which
activate CDK1/cyclin B to initiate mitosis. Recent reports
indicate that another dual specificity phosphatase, CDC25A,
plays a crucial role in G2-M events (Mailand et al., 2002).
CDC25A can bind and activate CDK1/cyclin B, and
downregulation by RNAi delays mitotic entry. In addition, the
overexpression of CDC25A abrogates the G2 DNA-damage
checkpoint (Mailand et al., 2002; Chow et al., 2003).
Therefore, it is possible to regard CDC25A as a master
activator of CDK/cyclin in the cell cycle, and the roles of
Fig. 5. Only the 309S mutant of CDC25B was distributed diffusely
with co-transfection of 14-3-3b . (A) Wild type CDC25B or different
CDC25B mutants with a single phosphorylatable serine were co-
transfected with 14-3-3b into HEK293 cells. (Upper panels)
Subcellular localization of CDC25B wild type and mutants. (Lower
panel) Corresponding images of nuclei. (B) Percentage of cells
transfected with mutant CDC25B 309S (shown in A) that express
CDC25B with nuclear, diffuse and cytoplasmic distribution. Over
200 cells expressing CDC25B were counted to determine the
percentage of cells that express CDC25B. Transfection with wild-
type CDC25B alone (WT), 309S mutant of CDC25B alone (309S)
and mutant 309S in combination with myc-tagged 14-3-3 b ( 309S
+14-3-3 b ) or myc-tagged 14-3-3 s ( 309S +14-3-3 s ). Error bars in
graphs represent the means+s.d. of three independent experiments.
Subcellular distribution of CDC25B: N>C, predominantly nuclear;

























































Fig. 6. 14-3-3e had effects similar to those of 14-3-3b on the subcellular localization of CDC25B. HE293 cells were transfected with (A) wild-
type CDC25B, (B) the 309S mutant or (C) the S309A mutant with or without 14-3-3 e . Over 200 cells expressing CDC25B were counted to
determine the percentage of cells that express CDC25B with nuclear, diffuse and cytoplasmic distribution. Error bars in graphs represent the
means+s.d. of three independent experiments. Subcellular distribution of CDC25B: N>C, predominantly nuclear; N=C diffuse; N<C,
predominantly cytoplasmic (C).
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CDC25B and CDC25C as being restricted to G2-M events to
activate CDK1/cyclin B.
It has been proposed that CDC25C inhibits human CDC25C,
by downregulating its phosphatase activity or by binding
14-3-3 after the phosphorylation of Ser216 (Peng et al., 1997;
Blasina et al., 1999; Furnari et al., 1999; Graves et al., 2001).
The amount of cellular CDC25C is essentially kept constant.
Therefore, a qualitative regulation of its functions, i.e. enzyme
activity and subcellular localization, is required to control cell
cycle progression. In the case of CDC25B, the protein
accumulates as the cell cycle progresses, reaching a maximum
at G2-M phase. Thus, controlling the expression of CDC25B
is an effective means of regulating its function. However, at G2
phase, when the CDC25B level is at its peak, an alternate way
of keeping it inactive is needed when its activation is
inappropriate. Recently, several groups have reported that the
binding of 14-3-3, specifically at Ser309 of CDC25B1 or
Ser323 of CDC25B2 or CDC25B3, results in the cytoplasmic
localization of CDC25B, supporting the theory of its
redistribution from the nucleus to the cytoplasm as a critical
G2-M checkpoint (Davezac et al., 2000; Forrest and Gabrielli,
2001).
In agreement with these reports, we found that 14-3-3 b and
14-3-3e bound specifically at Ser309 of CDC25B1 and that the
binding effectively redistributed CDC25B, decreasing its
amount in the nuclei. We consistently detected nuclear
localization in about 50% of the CDC25B-transfected cells.
Endogenous 14-3-3, detected with a pan-14-3-3 antibody, was
recovered as a complex with exogenous CDC25B. The co-
expression of 14-3-3 b or 14-3-3 e reduced the nuclear
localization of exogenous CDC25B by about 20%, but
endogenous 14-3-3 was recovered with exogenous CDC25B.
More than 95% of the introduced CDC25B was localized in
nuclei when the binding of 14-3-3 was abolished by a CDC25B
point mutation. Thus, it is reasonable to conclude that the
binding of 14-3-3 at Ser309 of CDC25B is essential for the
exclusion of CDC25B from the nucleus. We also presented
evidence that binding of 14-3-3 b to CDC25B slowed down the
nuclear import induced by LMB treatment. Since 14-3-3 b
specifically binds to Ser309, bound 14-3-3 should impair the
access of nuclear import cargos, such as importin, to the NLS.
In Xenopus, 14-3-3-binding to CDC25C was suggested to
mask its NLS, making its nuclear exclusion signal (NES)
available for the transfer of CDC25C to the cytoplasm
(Kumagai and Dunphy, 1999). The NLS in human CDC25B is
located at the same position relative to the 14-3-3-binding
site of CDC25C in Xenopus, i.e., about 30 amino acids
downstream of Ser309 (Davezac et al., 2000) (S.U., A.K.,
M.O., M.S., M.H., H.N., T.M., Y.I. and K.Y., unpublished
data). Therefore, the binding of 14-3-3 b or 14-3-3e at Ser309
could inactivate the NLS, which in turn would make the N-
terminal NES dominant. This idea is further supported by the
observation that the preferential binding of 14-3-3 s to Ser216
does not cause cytoplasmic redistribution of CDC25B because
Ser216 is too far away to allow 14-3-3 s to mask the NLS. We
also conclude from this result that the NES-like sequence
present in the C-terminus of all 14-3-3 subtypes does not
function as an NES. Thus, our results agree well with the
recently presented hypothesis that the binding of 14-3-3 does
not add an ‘attachable NES’ that targets proteins (Rittinger et
al., 1999; Brunet et al., 2002). Instead, it might serve other
functions, such as providing scaffolding or a cover that hides
specific motifs, such as NLS or NES (Muslin and Xing, 2000;
Tzivion et al., 2001; Yaffe, 2002).
Ser309 was shown to be phosphorylated by p38 MAP
kinase, and the kinase activity was necessary to maintain cell
cycle arrest at G2 in response to DNA damage caused by UV
light (Bulavin et al., 2001). One of the checkpoint kinases,
Chk1, can phosphorylate Ser309 to enhance 14-3-3-binding in
vitro (Forrest and Gabrielli, 2001) (S.U., A.K., M.O., M.S.,
M.H., H.N., T.M., Y.I. and K.Y., unpublished data). Although
co-expression of MKK6, Chk1 or Chk2 with CDC25B and 14-
3-3b enhanced the binding of 14-3-3 b to CDC25B, these
effects were not significant (S.U., A.K., M.O., M.S., M.H.,
H.N., T.M., Y.I. and K.Y., unpublished data). Therefore,
Ser309 seems to be constitutively phosphorylated, possibly by
p38 or C-TAK1. If phosphorylation of this serine is crucial for
the induction and/or maintenance of G2 arrest, the inactivation
of the phosphatase responsible for the dephosphorylation
might also occur, although enhanced checkpoint kinase activity
is usually thought to maintain the phosphorylation state. The
significance of the cytoplasmic localization of CDC25B in
terms of cell cycle regulation, especially at the G2 checkpoint,
is not clear. However, abrogation of the 14-3-3 binding site
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Fig. 7. Binding of 14-3-3 b to CDC25B
efficiently slowed down the nuclear
import of CDC25B induced by
leptomycin B (LMB). (A) HEK293
cells transfected with wild-type
CDC25B and treated with 20 ng/ml
LMB at for 3 hours. Transfected
CDC25B was detected with anti-FLAG
antibody. The upper and lower panels
show the results without or with LMB
treatment, respectively. (B) HEK293
cells transfected with wild-type
CDC25B alone or with 14-3-3 b .
Twenty-four hours after transfection, 20 ng/ml LMB were added to the cultures and
the percentage of cells exhibiting nuclear-specific localization of CDC25B was
determined at the indicated time-points: 0 (before addition of LMB), 1.5, 3 or 6 hours after the addition. Over 200 cells expressing CDC25B
were counted to determine the percentage of cells that express CDC25B. The percentage of cells with a nuclear localization (as shown in Fig. 4)
was determined from three independent experiments. d, CDC25B; s,CDC25B with 14-3-3 b .
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abolished G2-arrest and thus caused localization of CDC25B
to the nucleus. The overexpression of CDC25B is sufficient to
override the G2 DNA damage checkpoint (Miyata et al., 2001),
but in this case, Ser309 of the overexpressed CDC25B would
be phosphorylated as is the endogenous residue. In addition,
the amount of cellular 14-3-3 is obviously in excess of the
amount of CDC25B, and thus the equilibrium between 14-3-
3-bound CDC25B and unbound CDC25B should be the same
in transfected cells and in normal cells. If overexpression
enhances the probability of the localization of CDC25B in the
nucleus, CDC25B could counteract the inhibitory effects of
Wee1 kinase, leading to the activation of CDK1/cyclin B and
abrogation of the G2 checkpoint. Phosphorylation of Ser309
should be necessary to inhibit premature mitosis, but it is too
early to attribute maintained phosphorylation at the G2
checkpoint to the checkpoint kinases or to p38. So, if Ser309
is constantly phosphorylated, then its phosphorylation level
could never be enhanced because of DNA damage (Bulavin et
al., 2001). Indeed, no reports indicate a higher than normal
phosphorylation level of Ser309 or Ser323 in CDC25B2 or
CDC25B3 at the G2 checkpoint, although it is possible to
postulate a change from the maintenance kinases to the
checkpoint kinases at the checkpoint state to keep the
phosphorylation level constant (Bulavin et al., 2002). Thus, the
significance of the phosphorylation of Ser309, in combination
with the binding of 14-3-3 at the site, must await further
conclusions about the G2 checkpoint.
We have reported here the binding of 14-3-3 s at Ser216 of
CDC25B, which has not been reported previously. We have
also described another site, Ser137, that seems to provide
support for the binding of 14-3-3 s . The subtypes 14-3-3 b and
e have little preference for either of these sites, although both
serine residues partly satisfy the consensus-binding motif of
14-3-3 (RxxS). It is rare to find binding-preference differences
among 14-3-3 subtypes and it should be noticed that 14-3-3 s
does not prefer Ser309 for binding even though it is in one
of the typical 14-3-3 binding motifs. Interestingly, 14-3-3 s
also does not bind to CDC25C where Ser216 is located in a
typical 14-3-3 binding motif (RSxSMP) (Chan et al., 1999)
(S.U., A.K., M.O., M.S., M.H., H.N., T.M., Y.I. and K.Y.,
unpublished data). Two sites on CDC25B are required for the
efficient binding of 14-3-3 s , which means that 14-3-3 s must
be a dimer to bind efficiently to the two different sites on
CDC25B.
During the preparation of this manuscript an on-line report
was published, describing two sites, other than Ser323 of
CDC25B2, necessary for 14-3-3 binding (Giles et al., 2003).
Those two sites in CDC25B2, Ser151 and Ser230, are exactly
the same as Ser137 and Ser216 of CDC25B1 that have been
discussed here. We have demonstrated that 14-3-3 s binds to
these sites. It is well known that 14-3-3 s is one of the
downstream transcriptional targets of p53 (Hermeking et al.,
1997). There have been several reports that 14-3-3 s can
downregulate CDK activity by binding to it or that 14-3-3 s can
move the CDK1/cyclin B complex to the cytoplasm (Bulavin
et al., 2002). Here, we suggest that 14-3-3 s downregulates the
function of CDC25B and thereby acts as a G2-checkpoint
regulator. Our preliminary experiments indicate that the co-
expression of CDC25B and Chk1, but not MKK6 (that
activates p38), enhances phosphorylation at Ser137 and Ser216
(S.U., A.K., M.O., M.S., M.H., H.N., T.M., Y.I. and K.Y.,
unpublished data). Further studies are required to determine
whether the phosphorylation of both sites leads to the binding
of 14-3-3 s and to establish the consequences for CDC25B.
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